XELJANZ in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. XELJANZ can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.
XELJANZ in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy.
XELJANZ is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
The challenge of unresolved joint symptoms in PsA...
Among patients with PsA who had an inadequate response to csDMARDs:*181% of patients still had pain or swelling of their hands or feet1
... and the impact on quality of life:
Discontinuation rates for csDMARDs are 24-57%, primarily due to loss of response or tolerability issues2-4
* The population surveyed for this study included 67 patients with PsA who had an inadequate or lack of response to csDMARDs.
csDMARD=conventional synthetic disease-modifying antirheumatic drug; PsA=psoriatic arthritis.
- Giacomelli R et al. Rheumatology2015; 54: 792-797.
- Lebwohl MG et al. J Am Acad Dermato/2014; 70: 871-881.
- Lie E et al. Ann Rheum Dis2010; 69: 671-676.
- Nikiphorou E et al. Clin Rheumato/2014; 33: 609-614.
|XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.|
PP-XEL-GBR-1946 October 2019